IBRX 10-Q: SEC filing
ImmunityBio, Inc.
Filed with the SEC on · accession 0001326110-26-000099
IBRX filed a 10-Q (quarterly report) with the SEC on Nov 9, 2026. ImmunityBio, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and operations.
Summary of the filing
ImmunityBio, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and operations. The filing includes standard financial statements and disclosures.
Key details
✦ Ask GOAX AI about this filing — what it means for IBRX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for IBRX?
Click hereFrequently asked questions
What did IBRX file with the SEC on Nov 9, 2026?
IBRX filed a 10-Q (SEC filing). ImmunityBio, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and operations. The filing includes standard financial statements and disclosures.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
Other IBRX SEC filings
Get alerts when IBRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days